CO6241137A2 - Antagonistas ciclicos de peptido cxcr4 - Google Patents

Antagonistas ciclicos de peptido cxcr4

Info

Publication number
CO6241137A2
CO6241137A2 CO09135750A CO09135750A CO6241137A2 CO 6241137 A2 CO6241137 A2 CO 6241137A2 CO 09135750 A CO09135750 A CO 09135750A CO 09135750 A CO09135750 A CO 09135750A CO 6241137 A2 CO6241137 A2 CO 6241137A2
Authority
CO
Colombia
Prior art keywords
glu
group
asp
dglu
side chain
Prior art date
Application number
CO09135750A
Other languages
English (en)
Spanish (es)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6241137(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6241137A2 publication Critical patent/CO6241137A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CO09135750A 2007-05-30 2009-11-27 Antagonistas ciclicos de peptido cxcr4 CO6241137A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
CO6241137A2 true CO6241137A2 (es) 2011-01-20

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09135750A CO6241137A2 (es) 2007-05-30 2009-11-27 Antagonistas ciclicos de peptido cxcr4

Country Status (32)

Country Link
US (3) US7691813B2 (OSRAM)
EP (2) EP2160221B1 (OSRAM)
JP (1) JP5358564B2 (OSRAM)
KR (2) KR101169846B1 (OSRAM)
CN (1) CN101678213B (OSRAM)
AR (1) AR066648A1 (OSRAM)
AT (1) ATE516853T1 (OSRAM)
AU (1) AU2008260326B2 (OSRAM)
BR (1) BRPI0812134A2 (OSRAM)
CA (1) CA2688574C (OSRAM)
CL (1) CL2008001467A1 (OSRAM)
CO (1) CO6241137A2 (OSRAM)
CR (1) CR11105A (OSRAM)
CY (1) CY1111815T1 (OSRAM)
DK (1) DK2160221T3 (OSRAM)
DO (1) DOP2009000270A (OSRAM)
EA (1) EA017716B1 (OSRAM)
GT (1) GT200900304A (OSRAM)
HR (1) HRP20110551T1 (OSRAM)
IL (1) IL201685A (OSRAM)
JO (1) JO2776B1 (OSRAM)
MA (1) MA31666B1 (OSRAM)
MX (1) MX2009012952A (OSRAM)
MY (1) MY149432A (OSRAM)
NZ (1) NZ580849A (OSRAM)
PE (1) PE20090299A1 (OSRAM)
PL (1) PL2160221T3 (OSRAM)
PT (1) PT2160221E (OSRAM)
TN (1) TN2009000496A1 (OSRAM)
TW (1) TWI423987B (OSRAM)
WO (1) WO2008150689A1 (OSRAM)
ZA (1) ZA200908345B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
CA2838037C (en) * 2011-06-07 2019-09-17 Polyphor Ag Beta-hairpin peptidomimetics as cxc4 antagonists
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
CA3065086A1 (en) * 2017-09-05 2019-03-14 Mainline Biosciences High affinity cxcr4 selective binding conjugate and method for using the same
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Cxcr4結合性化合物もしくはその塩またはそれらと金属との錯体
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
WO2020053256A1 (en) 2018-09-12 2020-03-19 Technische Universität München Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
EP4232459A4 (en) * 2020-10-21 2024-12-04 Provincial Health Services Authority NEW COMPOUNDS TARGETING CXCR4
US20240124517A1 (en) * 2020-12-25 2024-04-18 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound containing n-substituted-amino acid residue
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
JP2025513489A (ja) * 2022-04-20 2025-04-24 プロビンシャル・ヘルス・サービシーズ・オーソリティ Cxcr4標的化合物、およびその作製方法、およびその使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規cxcr4アンタゴニスト
US8628750B2 (en) * 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment

Also Published As

Publication number Publication date
PT2160221E (pt) 2011-09-12
KR101319740B1 (ko) 2013-10-17
JO2776B1 (en) 2014-03-15
HK1141474A1 (en) 2010-11-12
JP2010529957A (ja) 2010-09-02
CA2688574C (en) 2014-02-18
CY1111815T1 (el) 2015-10-07
NZ580849A (en) 2012-03-30
AU2008260326B2 (en) 2011-07-21
USRE42274E1 (en) 2011-04-05
KR101169846B1 (ko) 2012-08-01
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
KR20100003737A (ko) 2010-01-11
TW200902556A (en) 2009-01-16
EP2377579A1 (en) 2011-10-19
GT200900304A (es) 2011-11-09
PL2160221T3 (pl) 2011-12-30
MX2009012952A (es) 2009-12-11
US20100130409A1 (en) 2010-05-27
AU2008260326A1 (en) 2008-12-11
IL201685A (en) 2015-04-30
JP5358564B2 (ja) 2013-12-04
CN101678213A (zh) 2010-03-24
PE20090299A1 (es) 2009-03-19
ATE516853T1 (de) 2011-08-15
BRPI0812134A2 (pt) 2014-11-18
TWI423987B (zh) 2014-01-21
EA017716B1 (ru) 2013-02-28
MA31666B1 (fr) 2010-09-01
CA2688574A1 (en) 2008-12-11
EP2160221B1 (en) 2011-07-20
CR11105A (es) 2010-04-12
CL2008001467A1 (es) 2008-12-05
US7691813B2 (en) 2010-04-06
IL201685A0 (en) 2010-05-31
EP2160221A1 (en) 2010-03-10
AR066648A1 (es) 2009-09-02
MY149432A (en) 2013-08-30
DOP2009000270A (es) 2010-01-15
EA200971129A1 (ru) 2010-04-30
TN2009000496A1 (en) 2011-03-31
US20080300177A1 (en) 2008-12-04
DK2160221T3 (da) 2011-09-19
HRP20110551T1 (hr) 2011-09-30
CN101678213B (zh) 2013-11-06
WO2008150689A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4
NZ601175A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
JP2010529957A5 (OSRAM)
NO20084008L (no) HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme
PE20121393A1 (es) Analogo peptidico de oxintomodulina
DE602007012443D1 (de) Zyklische angiotensinanaloga
NZ607892A (en) Tfpi inhibitors and methods of use
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
EP2590992A4 (en) OPIOID RECEPTOR AGONIST ANALOGUES OF ENDOMORPHINS
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
SI1987063T1 (sl) Peptidi in peptidni derivati, njihova priprava in tudi njihova uporaba za pripravo terapevtsko in/ali profilaktično aktivnega farmacevtskega sestavka
WO2002100885A3 (en) A penta- or tetrapeptide binding to somatostatin receptors and the use of the same
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
SG11201902818PA (en) Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
DE60031422D1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
Koizumi et al. Structure–activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
IN2014MN02080A (OSRAM)

Legal Events

Date Code Title Description
FG Application granted